Inmune Bio (INMB) Operating Leases (2019 - 2026)
Inmune Bio's Operating Leases was $593,000 in Q2 2026, up 156.7% from $231,000 a year earlier but down 26.4% from the prior quarter.
Powered by 
Analysis
Inmune Bio (INMB) Operating Leases (2019 - 2026) Analysis & Trends
At the end of FY2025, Operating Leases at Inmune Bio came in at $411,000, up 68.4% from FY2024.
- Operating Leases shows a five-year compound annual growth rate of 26.7% (FY2020 to FY2025).
- In earlier years, Operating Leases was $244,000 in FY2024 (-38.5%), $397,000 in FY2023 (-24.5%), $526,000 in FY2022 (+85.2%) and $284,000 in FY2021 (+125.4%).
- Quarterly Operating Leases has moved between $95,000 (Q3 2021) and $806,000 (Q1 2026) over five years.
- Compared with a year earlier, Operating Leases has increased for four straight quarters, with growth averaging 62.6% over the last eight quarters.
- The best year-over-year quarter for Operating Leases over five years was Q3 2022 (growth of 538.9%); the worst was Q1 2025 (a decline of 44.2%).
- Per Business Quant data, INMB's Operating Leases in the three quarters before Q2 2026 was $806,000 (Q1 2026), $411,000 (Q4 2025) and $623,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn |
| 10 | Inmune Bio | 55.31 Mn | -36.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 593,000.00 |
| Mar 31, 2026 | 806,000.00 |
| Dec 31, 2025 | 411,000.00 |
| Sep 30, 2025 | 623,000.00 |
| Jun 30, 2025 | 231,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Sep 30, 2024 | 284,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 397,000.00 |
| Sep 30, 2023 | 430,000.00 |
| Jun 30, 2023 | 463,000.00 |
| Mar 31, 2023 | 498,000.00 |
| Dec 31, 2022 | 526,000.00 |
| Sep 30, 2022 | 607,000.00 |
| Jun 30, 2022 | 645,000.00 |
| Mar 31, 2022 | 684,000.00 |
| Dec 31, 2021 | 284,000.00 |
| Sep 30, 2021 | 95,000.00 |
API Access
Inmune Bio Operating Leases API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=operating-leases&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "operating-leases", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=operating-leases&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();